Psilocybin and psilocin clinical trials

The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of Psilocybin Johns Hopkins University · 2026-10-16 · NCT07877987 Open-label, Single-arm fMRI Study Evaluating the Effects of Psilocybin on Craving in Nicotine Dependence. University of British Columbia · 2026-10-01 · NCT07852832 ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted Therapy University of Minnesota · 2026-09-22 · NCT07833761 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial University Health Network, Toronto · 2026-10-15 · NCT07820033 A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD) MycoMedica Life Sciences PBC · 2026-09-14 · NCT07818720 Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation Brown University · 2026-10-08 · NCT07818564 Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study ARQ National Psychotrauma Centre · 2026-08-28 · NCT07792538 High vs. Low-Dose Group-Based Psilocybin-Assisted Therapy (PAT) With or Without Mindfulness-Based (MB) Preparation and Integration for Demoralization in Adults With Advanced Cancer (PAT-MIND): A Pilot Feasibility 2x2 Factorial Multisite Trial University of Calgary · 2026-09-02 · NCT07791901 Psilocybin in the Treatment of Methamphetamine Use Disorder Peter Hendricks · 2026-09-21 · NCT07774702 Psilocybin Recovery Intervention for Stopping Methamphetamine Use Nicky Mehtani, MD, MPH · 2026-08-11 · NCT07756736 Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies University of New Mexico · 2026-08-04 · NCT07745569 The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease Yale University · 2026-09-28 · NCT07610369 Psilocybin-assisted Cognitive Behavioral Therapy for Depression University of California, Los Angeles · 2026-05-19 · NCT05227612 Psilocybin for Treatment of Obsessive Compulsive Disorder University of Arizona · 2024-08-30 · NCT03300947 Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression Joshua Rosenblat · 2026-07-30 · NCT07737990 Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder Tel-Aviv Sourasky Medical Center · 2026-07-30 · NCT07737054 Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin. Pontifícia Universidade Católica do Rio de Janeiro · 2026-07-28 · NCT07732166 Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease National Institute on Aging (NIA) · 2026-10-22 · NCT07721467 An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life Charles Raison · 2026-10-13 · NCT07719088 A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin Diamond Therapeutics Inc. · 2026-07-17 · NCT07710027 Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial Khyber Medical University Peshawar · 2026-07-14 · NCT07703722 The Effects of Psilocybin on Social Connectedness Yale University · 2026-07-09 · NCT07693153 A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. Francisco A Moreno · 2026-07-23 · NCT07347405 PRoMiSS: Psilocybin and the Role of Music in Set and Setting Johns Hopkins University · 2026-09-15 · NCT07180108 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study) University Hospital, Basel, Switzerland · 2025-05-28 · NCT06796361 Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought Johns Hopkins University · 2026-07-23 · NCT05301608 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects University Hospital, Basel, Switzerland · 2024-01-24 · NCT04227756 Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study Yale University · 2026-09-24 · NCT07449351 Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder Trent Emerick · 2026-08-06 · NCT07406828 The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma Baylor College of Medicine · 2026-01-22 · NCT06888128 Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling Robin Carhart-Harris, PhD, MA · 2026-06-05 · NCT05698511 The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation Sheppard Pratt Health System · 2025-12-24 · NCT05220410 Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life Charles S. Grob, M.D. · 2025-11-25 · NCT05403086 Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression. King's College London · 2025-09-10 · NCT07164755 Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers. University College, London · 2025-11-26 · NCT06815653 A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer University of Utah · 2024-03-20 · NCT04522804 Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression Federal University of Latin American Integration · 2026-03-27 · NCT06898606 SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression Washington University School of Medicine · 2023-01-30 · NCT05601648 Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder Icahn School of Medicine at Mount Sinai · 2025-05-14 · NCT06592833 Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study University of Wisconsin, Madison · 2026-09-29 · NCT07360301 Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study University of British Columbia · 2025-12-04 · NCT05585229 Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial Johns Hopkins University · 2026-07-17 · NCT06067737 Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers Hadassah Medical Organization · 2026-02-05 · NCT07079930 Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study COMPASS Pathways · 2024-12-04 · NCT05481736 Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults University of California, Berkeley · 2025-10-21 · NCT06367738 Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study Joshua Woolley, MD, PhD · 2026-09-03 · NCT04932434 PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment Johns Hopkins University · 2026-10-01 · NCT07610135 An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA) Beckley Psytech Limited · 2022-10-12 · NCT04905121 TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy M.D. Anderson Cancer Center · 2026-09-11 · NCT06200155 Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers University of Wisconsin, Madison · 2023-05-19 · NCT04842045 Visual Surround Suppression and Perceptual Expectation Under Psilocybin University of Minnesota · 2025-06-27 · NCT04424225 Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder University of Texas at Austin · 2025-11-26 · NCT06132178 The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression COMPASS Pathways · 2023-11-09 · NCT04739865 A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression Central Institute of Mental Health, Mannheim · 2025-01-20 · NCT04670081 Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study) University of Wisconsin, Madison · 2026-08-13 · NCT06692192 Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment University Hospital, Geneva · 2025-10-02 · NCT07164287 Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression National Institute of Mental Health, Czech Republic · 2022-05-20 · NCT05383313 Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial Johns Hopkins University · 2026-02-23 · NCT06005662 TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors M.D. Anderson Cancer Center · 2026-08-12 · NCT06801041 A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment NYU Langone Health · 2026-01-23 · NCT06796062 Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study Matthew Hicks · 2025-06-05 · NCT06372197 Double-blind Placebo-controlled Naturalistic Study of Microdosing With Psilocybin: Effects on Brain Activity, Behavior, Cognition, Creativity, and Mental Health National Council of Scientific and Technical Research, Argentina · 2021-12-16 · NCT05160220 Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants University Hospital, Basel, Switzerland · 2026-04-02 · NCT06180759 PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study) Imperial College London · 2024-11-06 · NCT06258031 A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine Kevin Murnane · 2025-10-07 · NCT06899594 Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence University of New Mexico · 2023-09-26 · NCT01534494 Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects University Hospital, Basel, Switzerland · 2025-03-05 · NCT05523401 Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans University of Zurich · 2025-11-19 · NCT06081179 Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study Yale University · 2026-06-04 · NCT05370911 Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression Sunnybrook Health Sciences Centre · 2026-03-30 · NCT06072898 Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms Centre Hospitalier Universitaire de Nīmes · 2026-07-01 · NCT07638553 Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial University of Colorado, Denver · 2026-05-22 · NCT06230757 The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD Emory University · 2026-10-01 · NCT07332143 Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression University of Zurich · 2022-04-29 · NCT03715127 Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder Portland VA Research Foundation, Inc · 2026-04-22 · NCT04982796 Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies University of New Mexico · 2026-03-20 · NCT07484906 Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder University of California, Los Angeles · 2026-04-07 · NCT06102434 Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study Johns Hopkins University · 2025-05-25 · NCT01943994 An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD Scottsdale Research Institute · 2026-07-29 · NCT07275970 Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults Wake Network, Inc. · 2022-06-30 · NCT04989972 Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation University of Wisconsin, Madison · 2026-07-07 · NCT04161066 Effects of Psilocybin in Obsessive Compulsive Disorder Johns Hopkins University · 2026-09-04 · NCT05546658 Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial University Health Network, Toronto · 2026-06-23 · NCT07048743 Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · 2025-03-13 · NCT00302744 Mechanistic Studies of Psilocybin in Headache Disorders Yale University · 2026-07-13 · NCT06464367 Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) Centre for Addiction and Mental Health · 2026-10-19 · NCT06512220 Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study). University Hospital, Basel, Switzerland · 2025-04-11 · NCT05695495 Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb Pain University of California, San Diego · 2026-10-09 · NCT05224336 Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms Imperial College London · 2024-10-24 · NCT03429075 Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder Johns Hopkins University · 2026-03-18 · NCT06660381 An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study) Charles Raison · 2026-08-10 · NCT06512194 Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study Gustavo Vazquez · 2026-03-18 · NCT06818994 A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer University of Washington · 2025-10-14 · NCT06644170 NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System. NWTraumatherapies · 2022-11-16 · NCT05042466 Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study Anders Fink-Jensen, MD, DMSci · 2024-07-12 · NCT04718792 Psilocybin-Assisted Therapy for Prolonged Grief University of Virginia · 2026-06-23 · NCT06724289 A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression Washington University School of Medicine · 2026-05-20 · NCT07582120 Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN Unity Health Toronto · 2025-03-30 · NCT06731335 A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin University of Wisconsin, Madison · 2023-05-15 · NCT05467761 The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC) Emory University · 2025-07-23 · NCT05506982 Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial University of Calgary · 2024-05-07 · NCT05995769 Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression University of Helsinki · 2017-12-21 · NCT03380442 Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND) King's College London · 2026-07-23 · NCT05723276 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD). Apex Labs Ltd. · 2023-11-29 · NCT06141876 Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior Johns Hopkins University · 2016-02-24 · NCT00802282 The Neurobiological Effect of 5-HT2AR Modulation Gitte Moos Knudsen · 2024-12-16 · NCT03289949 The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults Region Skane · 2026-08-14 · NCT07169747 Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study Imperial College London · 2025-12-05 · NCT06798636 Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial Centre for Addiction and Mental Health · 2026-02-12 · NCT07405606 Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder Johns Hopkins University · 2024-01-05 · NCT05562973 Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures Centre Hospitalier Universitaire de Nīmes · 2025-08-21 · NCT06647056 Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial Unity Health Toronto · 2026-10-06 · NCT06386003 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer Sunstone Medical · 2026-05-06 · NCT05947383 Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II Yale University · 2023-10-12 · NCT03806985 A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics Usona Institute · 2023-08-15 · NCT05478278 Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults University of California, San Francisco · 2025-06-10 · NCT05317689 A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer. Psyence Australia Pty Ltd · 2026-03-03 · NCT07072728 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD) Usona Institute · 2026-10-21 · NCT06308653 Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder University of New Mexico · 2026-05-22 · NCT07506395 Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study University of North Carolina, Chapel Hill · 2026-05-06 · NCT06303739 The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training Felix Mueller · 2025-04-14 · NCT05570708 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants MycoMedica Life Sciences PBC · 2025-06-12 · NCT06643637 Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2) University Health Network, Toronto · 2026-07-09 · NCT06341426 An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) Sheppard Pratt Health System · 2024-08-09 · NCT04433858 Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment Centre for Addiction and Mental Health · 2026-10-05 · NCT06041152 Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia NYU Langone Health · 2026-09-15 · NCT07607938 Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY) Alan Davis · 2026-05-14 · NCT07216404 Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators Milan Scheidegger · 2023-09-21 · NCT05780216 Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease Johns Hopkins University · 2026-09-04 · NCT04123314 Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) Yale University · 2026-07-07 · NCT06160284 Safety for Home Administration of Microdose Psilocybin Use Johns Hopkins University · 2026-08-14 · NCT06450210 Psilocybin With Intracranial Neural Sensing Joshua Woolley, MD, PhD · 2025-06-06 · NCT06919640 Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial Lakshmi N Yatham · 2026-09-15 · NCT06943573 Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health University of Alabama at Birmingham · 2026-03-11 · NCT05227742 Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome. NYU Langone Health · 2026-03-05 · NCT06760533 A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)? Anna Rose Childress, Ph.D. · 2025-10-29 · NCT06786325 A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD) Usona Institute · 2026-04-22 · NCT03866174 Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects University Hospital, Basel, Switzerland · 2026-06-25 · NCT06884514 Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy University of California, San Diego · 2022-07-25 · NCT04661514 Psilocybin for Treatment of Obsessive Compulsive Disorder Francisco A Moreno · 2026-05-12 · NCT06992999 An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder University of California, San Francisco · 2024-09-25 · NCT05065294 Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial Centre for Addiction and Mental Health · 2026-10-21 · NCT06518720 Psilocybin and Affective Function in Chronic Lower Back Pain Depression Johns Hopkins University · 2026-09-04 · NCT06355414 The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function Manoj Doss · 2026-06-15 · NCT07079852 Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism Healing Advocacy Fund · 2025-09-24 · NCT07189988 Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder NYU Langone Health · 2026-09-02 · NCT06349083 Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study) University Hospital, Basel, Switzerland · 2025-03-27 · NCT06899334 Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter NYU Langone Health · 2025-12-22 · NCT07296328 A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study Filament Health Corp. · 2024-10-30 · NCT06666010 A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis. King's College London · 2019-08-13 · NCT03661125